Company / PP&E (Net)
Cytek Biosciences, Inc. PP&E (Net) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$18.0M
FY2025
5-year range
$5.9M / $18.4M
FY2021-FY2025
Trend
+0.3%
vs FY2024
Sector context
#113 of 132
Health Care
What the data says
Cytek Biosciences, Inc.'s pp&e (net) of $18M is lower than 86% of companies in the Health Care sector (FY2025). Declined from $18M to $18M over the past 2 years.
Based on SEC 10-K filings.
$18M in FY2025 with a 5-year CAGR of +53.1%.
Declined from $18M to $18M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +9.6%
- 5-Year CAGR
- +53.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 132This company $18.0M Sector average $1.4B
▼
-98.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +53.1%, indicating consistent growth.
- In FY2025, pp&e (net) increased 0.3% year-over-year.
- Ranks #113 out of 132 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.0M | +0.3% |
| FY2024 | $18.0M | -2.4% |
| FY2023 | $18.4M | +34.5% |
| FY2022 | $13.7M | +133.8% |
| FY2021 | $5.9M | +173.4% |
| FY2020 | $2.1M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026